Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-Arm Study to Assess the Safety of Darbepoetin Alfa Manufactured by a Serum Free Bioreactor Technology in Subjects With Chronic Kidney Disease

NCT00093977 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00093977
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00093977 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-Arm Study to Assess the Safety of Darbepoetin Alfa Manufactured by a Serum Free Bioreactor Technology in Subjects With Chronic Kidney Disease
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2004
Completion date
January 31, 2007
Enrollment
1,100 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, kidney disease